- Home
- CLW vs DCTH Comparison
CLW vs DCTH Comparison
Compare CLW & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLW
- DCTH
- Stock Information
- Founded
- CLW 2005
- DCTH 1988
- Country
- CLW United States
- DCTH United States
- Employees
- CLW N/A
- DCTH N/A
- Industry
- CLW Paper
- DCTH Medical/Dental Instruments
- Sector
- CLW Basic Materials
- DCTH Health Care
- Exchange
- CLW Nasdaq
- DCTH Nasdaq
- Market Cap
- CLW 348.3M
- DCTH 388.3M
- IPO Year
- CLW N/A
- DCTH N/A
- Fundamental
- Price
- CLW $22.01
- DCTH $11.65
- Analyst Decision
- CLW Buy
- DCTH Strong Buy
- Analyst Count
- CLW 1
- DCTH 4
- Target Price
- CLW $36.00
- DCTH $24.50
- AVG Volume (30 Days)
- CLW 197.2K
- DCTH 565.2K
- Earning Date
- CLW 11-03-2025
- DCTH 11-07-2025
- Dividend Yield
- CLW N/A
- DCTH N/A
- EPS Growth
- CLW 345.10
- DCTH N/A
- EPS
- CLW 12.12
- DCTH 0.06
- Revenue
- CLW $1,550,400,000.00
- DCTH $70,240,000.00
- Revenue This Year
- CLW $12.75
- DCTH $159.22
- Revenue Next Year
- CLW $1.60
- DCTH $41.22
- P/E Ratio
- CLW $1.76
- DCTH $208.23
- Revenue Growth
- CLW 34.73
- DCTH 491.35
- 52 Week Low
- CLW $20.84
- DCTH $8.08
- 52 Week High
- CLW $33.57
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- CLW 42.70
- DCTH 58.68
- Support Level
- CLW $21.08
- DCTH $10.81
- Resistance Level
- CLW $21.92
- DCTH $11.32
- Average True Range (ATR)
- CLW 0.61
- DCTH 0.46
- MACD
- CLW 0.27
- DCTH 0.14
- Stochastic Oscillator
- CLW 72.22
- DCTH 85.03
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.